InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,991.39
(
0.32%
)
Post# of 251797
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119614
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 235656

Saturday, 06/26/2021 7:11:23 PM

Saturday, June 26, 2021 7:11:23 PM

Post# of 251797
ABUS_reports_additional—(blah)—phase-1_data_for_AB-729_in_HBV:

https://finance.yahoo.com/news/arbutus-announces-data-ab-729-111500598.html

https://investor.arbutusbio.com/static-files/a7e1c49a-09eb-47a7-9e96-48fe9f7faef1

AB-729 is in injected RNAi agent that targets HBsAg.

Not much has changed since the previous update on this phase-1 trial in late 2020 (#msg-159504853). Despite the inclusion of two new dosing cohorts (60mg q8w and 90mg q4w), HBsAg reduction is middling (1.6-1.8 logs at 24w — see slide #9 in the second link above), and it is essentially the same for all three dosing cohorts, which is not a great sign.

Please see #msg-155730326 and #msg-155712858, and #msg-157913492 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up